% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sprokkerieft:293782,
      author       = {J. Sprokkerieft and J. N. van der Beek and F. Spreafico and
                      B. Selle$^*$ and T. Chowdhury and N. Graf and A. C.
                      Verschuur and R. Dandis and A. Bex and J. I. Geller and G.
                      A. M. Tytgat and M. M. van den Heuvel-Eibrink},
      title        = {{O}utcome after treatment with axitinib in children, young
                      adults, and adults with renal cell carcinoma: a narrative
                      review.},
      journal      = {Critical reviews in oncology, hematology},
      volume       = {204},
      issn         = {0737-9587},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2024-01940},
      pages        = {104523},
      year         = {2024},
      note         = {Volume 204, December 2024, 104523},
      abstract     = {Renal cell carcinoma (RCC) is a very rare type of renal
                      cancer in children and young adults. When metastasized or
                      recurrent, no standards of care are available, and outcome
                      is still poor. The tyrosine kinase inhibitor axitinib is
                      approved for treatment of RCC in adults, but its effects in
                      children and young adults with RCC remains unclear. Due to
                      the histological and biological differences between children
                      and adults, it is difficult to extrapolate knowledge on
                      treatments from the adult to the pediatric and young adult
                      setting. This paper summarizes the clinical characteristics
                      and outcomes of patients with RCC who were treated with
                      axitinib, with the aim to gain insight in the clinical
                      efficacy of this compound in this young patient group.},
      subtyp        = {Review Article},
      keywords     = {Pediatric (Other) / axitinib (Other) / renal cell carcinoma
                      (Other) / young adult (Other)},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39326645},
      doi          = {10.1016/j.critrevonc.2024.104523},
      url          = {https://inrepo02.dkfz.de/record/293782},
}